drugset / Trial / NCT00337389
Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.
RandomizedParallel-groupOpen-labelTreatment
Summary
To compare the progression-free survival time (PFS) in patients treated with 5-FU modulated with CoFactor (plus bevacizumab) to 5-FU modulated with leucovorin (plus bevacizumab) in patients with Metastatic Colorectal Cancer.
Timeline
- Start
- 2006-05
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FOLITIXORIN | Small molecule | — | — |
| Comparator | Leucovorin | Small molecule | — | — |
| Background | Bevacizumab | Monoclonal antibody | — | — |
| Background | fluorouracil | Small molecule | — | — |